

1 **Considering aspects of the 3Rs principles within experimental animal biology**

2 Lynne U. Sneddon^{1*}, Lewis G. Halsey², and Nic R. Bury³

3

4 ¹Institute of Integrative Biology, University of Liverpool, The BioScience Building, Liverpool,

5 L69 7ZB, UK

6 ²Department of Life Sciences, University of Roehampton, London, SW15 4JD, UK

7 ³University of Suffolk, Faculty of Health Sciences and Technology, James Hehir Building,

8 Neptune Quay, Ipswich, IP4 1QJ, Suffolk, United Kingdom.

9

10

11 *Author for correspondence: lsneddon@liverpool.ac.uk

12

13

14 **ABSTRACT**

15 The 3Rs – Reduction, Replacement and Refinement – are embedded into the legislation and
16 guidelines governing the ethics of animal use in experiments. Here, we consider the
17 advantages of adopting key aspects of the 3Rs into experimental biology, represented mainly
18 by the fields of animal behaviour, neurobiology, physiology, toxicology and biomechanics.
19 Replacing protected animals with less sentient forms or species, cells, tissues or computer
20 modelling approaches has been broadly successful. However, many studies investigate
21 specific models that exhibit a particular adaptation, or a species that is a target for
22 conservation, such that their replacement is inappropriate. Regardless of the species used,
23 refining procedures to ensure the health and wellbeing of animals prior to and during
24 experiments is crucial for the integrity of the results and legitimacy of the science. Although
25 the concepts of health and welfare are developed for model organisms, relatively little is
26 known regarding non-traditional species that may be more ecologically relevant. Studies
27 should reduce the number of experimental animals by employing the minimum suitable
28 sample size. This is often calculated using power analyses, which is associated with making
29 statistical inferences based on the *P* value, yet *P* values often leave scientists on shaky ground.
30 We endorse focussing on effect sizes accompanied by confidence intervals as a more
31 appropriate means of interpreting data; in turn, sample size could be calculated based on
32 effect size precision. Ultimately, the appropriate employment of 3Rs principles in
33 experimental biology empowers scientists in justifying their research, and results in higher-
34 quality science.

35

36

37 **KEY WORDS:** Animal welfare; Environmental enrichment; Replacement; Reduction;
38 Refinement; Toxicology

39

40

41

42 **INTRODUCTION**

43 Animal research is essential for the advancement of new technologies and medicines crucial
44 to improving human and animal health. It is also vital for our understanding of fundamental
45 animal biology, as well as essential areas of applied animal science, such as how animals
46 function in the face of climate change or anthropogenic disturbance. Further, studies
47 exploring animal health and welfare enable us to manage captive animals more effectively,
48 and prevent poor welfare that leads to disease. Against this backdrop of necessary animal
49 research, scientists are increasingly asked to justify their experimental approaches when using
50 protected animals. This is partly driven by demands from the general public that the use of
51 animals in research is moral and ethically justifiable. A recent poll in the United States
52 demonstrated that 50% of the public were opposed to the use of animals in research (Pew
53 Research Center, 2015). In 2015, nine European countries presented a petition to the
54 European Commission (EC) to ban animal research. However, the EC opposed this movement,
55 but responded by stating that ethical justification and adoption of the 3Rs (Reduction,
56 Replacement and Refinement) is a must for experimental studies (EC, 2015). Of course, it is
57 in scientists' interest to adopt an ethical and humane approach to husbandry and experimental
58 design, since healthy animals produce robust, reliable results, underlying valid scientific
59 outputs. For example, improved husbandry and handling of rodents reduces stress, and this

60 leads to less variable data and more meaningful results (Hurst & West, 2010; Singhal et al.,
61 2014). Embedding the 3Rs principles into scientific planning and execution therefore directly
62 benefits data quality.

63 The 3Rs concepts were first developed by Russell and Burch (1959) and have become
64 rooted in legislation and guidelines concerning animal experimentation in many countries (Fig.
65 1). Refinement involves either reducing the invasiveness of a technique or improving animal
66 welfare and health during scientific studies. This can be achieved through better assessment of
67 the animal's state or improved husbandry and housing. Reduction concerns minimising the
68 number of animals used to effectively achieve the goals of an experiment. Replacement
69 involves the adoption of alternatives to protected animals – such alternatives may be non-
70 protected species or immature forms; cell lines or cultured tissues; mathematical modelling of
71 existing data sets or conceptual data; or the use of humans, their tissues or their cells (with
72 permission). Many funding bodies in the UK and Europe now have dedicated application
73 sections on each of the 3Rs that must be completed, thus requiring justification of the use of
74 protected animals. In this Commentary, we discuss current knowledge and recent
75 developments in the 3Rs relevant to the field of experimental animal biology. Our views are
76 fuelled by a recent symposium funded by the Society for Experimental Biology (SEB) and co-
77 funded by the Association for the Study of Animal Behaviour (ASAB), held in London in
78 2016 (Knight, 2016).

79

80 **REFINEMENT**

81 Refinement is an integral component of improving laboratory animal welfare, which is vital
82 for healthy biological functioning and a normal behavioural repertoire. Therefore, refining
83 procedures to reduce their invasiveness or the degree of stress they cause and perfecting

84 housing and husbandry should be the goal of any scientist. However, some animal groups
85 have received relatively little attention in this area, resulting in less-developed tools or
86 knowledge to assess their health and welfare (e.g. pain assessment is highly developed for
87 mammals compared with other animal groups, Sneddon et al., 2014; Sneddon, 2015).
88 Additionally, good husbandry practices improve animal wellbeing and the reliability of
89 experimental results; thus, it is important to know what different species require in their
90 environment in order to maintain their health and welfare. The necessity to develop
91 refinement recommendations and good laboratory practices for both traditional and non-
92 traditional species has driven this vibrant research field.

93 ***Environmental enrichment***

94 The EC Directive (2010) proposes that all protected animals should have enriched
95 environments in which to live. Enrichment can involve physical objects that either make an
96 environment more complex (e.g. plastic plants, gravel substrate and overhead cover in a fish
97 tank; Pounder et al., 2016) or can be used by the animals (e.g. perches in bird enclosures;
98 Kalmer et al., 2010). Alternatively, enrichment can involve appropriate social housing (e.g.
99 gregarious species not kept in isolation or territorial species held in groups), apparatus to
100 allow exercise (e.g. rodent running wheel), nutritional enrichment (e.g. diversity of feeding
101 regimens) and sensory stimulation (visual, olfactory and aural; see Singhal et al., 2014).
102 Understanding the appropriate type of enrichment can have tremendous benefits, reducing
103 stress and the inter-individual variation in behavioural and physiological variables (Singhal et
104 al., 2014). Preference testing can provide insight into what an animal would choose, although
105 this depends on the resources tested and so caution should be applied. As an example of the
106 effect that refinement can have, it is known that zebrafish have relatively smaller brains when
107 reared in barren conditions compared with enriched tanks (DePasquale et al., 2016), which
108 might indicate chronic sensory deprivation. This raises both ethical issues and concerns about

109 the veracity of neurobiological and behavioural research conducted on such individuals.
110 Indeed, zebrafish housed for seven months in barren tanks choose to interact with enrichment
111 when given the option (Schroeder et al., 2014). In addition, rainbow trout housed in enriched
112 tanks recover from stressors more quickly (Pounder et al., 2016; Fig. 2), and it is known that
113 background colour influences growth rates, physiological stress and behaviour in *Xenopus*
114 (Holmes et al., 2016; Fig. 2). These studies can have real impact upon husbandry protocols,
115 which are essential for guaranteeing the health of experimental animals.

116 ***Refining experimental procedures***

117 Refinements to reduce the invasiveness of a procedure can be as simple as improving the
118 manner in which animals are handled. Hurst and West (2010) showed that handling mice by
119 allowing them to voluntarily sit in a cupped hand or enter a plastic tunnel reduced anxiety and
120 stress compared with the traditional method of picking up mice by the tail. Non-invasive
121 imaging of molecular responses – using techniques such as magnetic resonance imaging
122 (MRI), positron emission tomography (PET), single positron emission computed tomography,
123 ultrasound and optical imaging (bioluminescence and fluorescence) – circumvents the need to
124 humanely kill or biopsy animals for samples: imaging can be performed *in vivo* and in real
125 time, negating the necessity for sampling groups of animals at various time points (O’Farrell
126 et al., 2013). These imaging techniques can monitor molecular and cellular changes non-
127 invasively in intact animals, although repeated anaesthesia may be necessary and is likely to
128 be stressful. These approaches have facilitated significant advances in preclinical research and,
129 consequently, fewer animals are required, individuals can be tracked over a longer time period
130 and they are not subjected to invasive, potentially painful, procedures (reviewed in O’Farrell
131 et al., 2013). Thus, there is scope for these non-invasive technologies to be applied to a wide
132 variety of contexts in experimental animal biology, but there is a substantial economic cost to
133 employing imaging techniques.

134 Assessing welfare is key to ensuring that animals are healthy before, during and after
135 experiments where post-surgical care is vital. Laboratory rodents have been well studied, and
136 key behavioural changes (Sneddon et al., 2014), as well as the more recent grimace scales for
137 rats, mice and rabbits, can be used to gauge their pain levels (Langford et al., 2010; Sotocinal
138 et al., 2011; Keating et al 2012 see NC3Rs, 2017 for scales). Extensions of the grimace scales
139 have been applied to horses (Dalla Costa et al 2014), and are likely to be applicable to other
140 non-model mammals. Although non-mammalian animals are less well studied, advances are
141 being made. For example, fin clipping of zebrafish, a routine procedure for genomic screening,
142 is normally conducted under anaesthesia, but analgesics are not routinely applied. However,
143 Schroeder and Sneddon (2017) demonstrated substantial changes in behaviour after fin
144 clipping that were ameliorated by pain-relieving drugs (Fig. 2). Rather than injecting these
145 relatively small fish, this study showed that adding the drugs to the tank water effectively
146 reduces pain, and this could be extrapolated to other aquatic species. Further research is
147 required to develop robust indicators of welfare and health in a variety of common laboratory
148 models, since species can differ in their expression of poor welfare. Automated monitoring of
149 animal health through non-invasive use of behavioural recording equipment would be ideal
150 (e.g. Deakin et al., 2017 MS submitted; Rushen et al., 2012; Noldus, 2016).

151 *Refinement for non-traditional experimental species*

152 Although much is known about refinement in model organisms, many experimental
153 animal biologists use non-traditional species to answer important and ecologically relevant
154 physiological questions. While refinements therefore need to be employed on a species-by-
155 species basis, general principles from model organisms should make a good starting point
156 from which welfare testing can begin. A further confounding issue is that many experiments
157 take place in the field rather than a laboratory. General principles of refinement can be applied,
158 with the capture, handling, tagging and sampling of animals done in the most humane way. If

159 invasive methods are appropriate, ways to improve animal welfare and health can be
160 considered. Obviously it can be difficult to assess health and welfare if the animals are
161 returned to their natural environment. However, recapture studies (e.g. intraperitoneal tags,
162 Gardner et al., 2015; radio collars, Hopkins & Milton, 2016) and assessment of subsequent
163 breeding success (Phillips et al., 2003) can provide some measure of survivorship. This is
164 pertinent to understanding how previous procedures may have affected the animals, given that
165 survival and reproduction can be affected by vulnerability to predators, and the ability to
166 harvest resources and to cope with intraspecific agonistic interactions.

167

168 **REPLACEMENT**

169 *Replacement in a comparative physiology context*

170 Studying physiological adaptation or the response of vulnerable species to environmental
171 perturbations is at the core of comparative and conservation physiology. Krogh's principle
172 states that "for such a large number of problems there will be some animal of choice, or a few
173 such animals, on which it can be most conveniently studied." Thus, often in the comparative
174 and conservation disciplines, animals cannot be easily replaced, and reduction and refinement
175 are more realistic ethical strategies. However, the evolutionary conservation of physiological
176 traits throughout the eukaryotes means that alternative non-vertebrate organisms can provide
177 valuable information where processes are shared with sentinel organisms, enabling
178 experimental biologists to embrace the replacement approach. For example, the cell behaviour
179 of the soil-dwelling amoeba *Dichtyostelium* can be used as a rapid screen for the effects of
180 medicinal products (Otto et al., 2016). As another example, the simplified neuronal network
181 of the pond snail *Lymnaea stagnalis* can be used to study the neurobiological processes
182 involved in decision making and motivational state (Crossley et al., 2016), as well as the

183 effects of stressors on memory formation (Lukowiak et al., 2014). In addition, *ex vivo* systems,
184 organoid cell cultures and immortalised cell lines are often utilised and, although they cannot
185 replace the complex interactions between tissues in intact vertebrates, they can provide insight
186 when investigating intra- and inter-cellular biological processes or tissue-level responses. The
187 key is to find the right non-vertebrate model organism or *in vitro* system to answer the
188 question of interest – a concept that will be very familiar to a comparative physiologist
189 audience.

190 ***Factors driving replacement research***

191 Recent advancements in replacement approaches within experimental biology have occurred
192 in identifying alternatives to the use of vertebrates in regulatory tests; tests which are required
193 by law as part of any chemical's risk assessment, such as OECD 305 (Bioaccumulation in
194 Fish: Aqueous and Dietary Exposure) and OECD 203 (Fish, Acute Toxicity Test) (Lillicrap et
195 al., 2016) for aquatic environmental risk assessment. For example, within Europe, the
196 regulations concerning the Registration, Evaluation, Authorisation and restriction of
197 Chemicals (REACH) have resulted in many thousands of chemicals requiring further animal
198 testing. Though the European Union (EU) did not ban animal testing as part of REACH,
199 animal welfare legislation requires the incorporation of the 3Rs principles. This has led to a
200 strong impetus for regulatory authorities to accept replacement test systems as part of risk
201 assessment evaluation (Burden et al., 2016). Acceptance requires a rigorous scientific
202 understanding about whether such alternatives adequately reflect physiological processes
203 observed in intact adult fish.

204 ***Suitable replacements***

205 *Embryonic and young forms*

206 The young forms of many species are not considered to suffer. Thus, the United Kingdom
207 Animals (Scientific Procedures) Act 1986 and European Directive 2010/63 specifies that fish
208 become a protected animal once they are capable of independent feeding [e.g. zebrafish after
209 120 hours post fertilization (120 hpf) at 28°C; Strähle et al., 2012]. However, this is not case
210 for all countries (Box 1). This threshold is based upon the concept that, before this stage, fish
211 are not fully developed and are unable to experience external stimuli, meaning there is no
212 obligation to report the number of fish embryos used. But recent studies show that 120 hpf
213 larval zebrafish respond to noxious stimuli, and that this is ameliorated by administration of
214 pain-relieving drugs (Lopez Luna et al., 2017a; 2017b). From a regulatory perspective, the
215 fish embryo toxicity (FET) test, which lasts for 96 hpf for zebrafish (Henn and Braunbeck,
216 2011), correlates well with adult acute toxicity (Lammer et al., 2009, Scholz et al 2014), and
217 the OECD have approved OECD 236 test FET guidelines (Busquets et al., 2014).

218 In basic research, embryos, including those from chickens, have been used extensively
219 to study the development and functioning of organs within the context of a whole organism
220 (e.g. Tazawa et al 2002). Zebrafish embryos are now used for many basic physiological and
221 behavioural studies; for example, sophisticated video imaging packages can be used to record
222 their movement in response to chemical exposure (e.g. Nüßer et al., 2016), translucent fish
223 embryos provide an ideal model to study cardiovascular function (Incardona and Scholz,,
224 2016, Yozzo et al., 2013), and genetic manipulation has enabled a study of the functional
225 regulation of ionoregulation (Cruz et al 2013, Guh et al 2015).

226 *Cell lines and organoid cultures*

227 The EU's decision to ban animal testing for cosmetics ingredients (EU1223/2009) provided
228 the momentum to develop alternative mammalian *in vitro* models to identify chemicals that
229 pose a health risk. In addition, there is a long history of the development of fish cell lines

230 from a variety of tissues and organisms (Bols et al., 2005). For example, the cell line derived
231 from the gills of rainbow trout (RTgill-W1) (Bols et al., 1994) is promising as a replacement
232 for OECD203 (Tanneberger et al., 2013; Lillicrap et al., 2016) and for chronic toxicity tests.
233 But further basic mechanistic understanding of how cell growth in culture correlates with
234 somatic growth in a whole fish is necessary for *in vitro* to *in vivo* extrapolation (Stadnicka-
235 Michalak et al., 2015).

236 Extensive research has gone into mammalian tissue and stem cell-derived organoid cultures
237 for disease and drug development research (Liu et al 2016; Muthuswamy, 2017). The time it
238 takes to develop these types of *in vitro* model may make them unsuited to comparative
239 physiological studies, but they are of interest for basic research because these systems better
240 replicate in situ tissue physiology than do 2-D cell cultures.

241 A further development is the potential replacement of the OECD 305 test, which has
242 led to technical advancements in fish *in vitro* organoid cultures (Baron et al., 2012, Schnell et
243 al., 2016). Data on the basic characteristics of chemical uptake, metabolism and excretion by
244 these organoid cultures provide the scientific rigor which supports their use in alternative
245 testing procedures for bioconcentration studies. For example, a primary fish gill culture
246 technique has been developed from which two fish (subject only to humane killing) can
247 produce between 48 and 72 cell culture inserts: harvesting of cells for primary culture in the
248 UK is not defined as a procedure, so this approach replaces the use of animals (Schnell et al.,
249 2016). The system has been used to study branchial physiological processes, such as ammonia
250 excretion and endocrine control of epithelial tight junction formation (see Bury et al., 2014).
251 The liver is the main site of metabolism and excretion, and a number of *ex vivo* and *in vitro*
252 methods (e.g. liver slices, primary hepatocytes, S9 fraction and cell cultures) have been
253 deployed to estimate the ability of the liver to metabolise compounds (see Weisbrod et al.,
254 2009). Recent advances in liver organoid cell culture techniques generate three-dimensional

255 spheroidal hepatocytes (Uchea et al., 2013; Baron et al., 2012) that better represent the
256 metabolic capabilities of the intact liver (Baron et al., 2017). Encouragingly, there are a
257 number of studies that extrapolate the hepatocyte *in vitro* biotransformation data to *in vivo*
258 scenarios (Nichols et al., 2006, 2007; Cowan-Ellsberry et al., 2008), allowing derivation of
259 bioconcentration factors BCF (Nichols et al., 2013).

260 High-throughput FET or *in vitro* screens are being used as part of the Adverse
261 Outcome Pathways (AOP) conceptual framework to identify molecular initiating events (MiE)
262 induced by a compound (Ankley et al., 2010, Wittwehr, et al., 2017). AOPs aim to use
263 empirical mechanistic data at lower levels of biological organisation (e.g. cells) to predict
264 higher level effect (e.g. whole-organism toxicity). MiE identification can uncover chemicals
265 of unknown toxic action or off-target effects (Villeneuve et al., 2014). Ultimately, it is
266 envisaged that the AOP concept can lead to computer-based predictive models to assist
267 environmental risk assessment (Wittwehr et al., 2017), replacing many, if not all, animals
268 used in regulatory procedures. The AOP concept is a wonderful example of how toxicology
269 and physiology are intertwined. The wealth of data on the downstream effects of stimulating a
270 receptor within a cell, whether by a synthetic or natural chemical, will potentially aid the
271 identification of regulatory mechanisms and feedback control of physiological processes.

272 **REDUCTION**

273 ‘Reduction’ proposes that researchers reduce the number of experimental animals used such
274 that just enough data and no more are obtained to give sufficiently informative results.
275 Experimental designs that incorporate stronger perturbations or support greater measurement
276 precision improve the signal-to-noise ratio of the data analysis (see Halsey, 2007), which
277 enables the sample size to be reduced. Put simply, cleaner and clearer experiments require
278 fewer experimental animals for the analysis to be robust. Authors such as McClelland (2000),

279 Eng (2003) and de Boo and Hendriksen (2005) suggest various avenues for improving
280 measurement precision, including: (1) using more reliable measures, repeating measurements,
281 using experienced staff and well-honed experimental procedures; (2) including measures of
282 concomitant variables (such as body mass) to account for measurable variability; (3)
283 experimentally reducing variability, e.g. by working with one age group or sex [the latter
284 pertains to both study animal and researcher (Sorge et al., 2014)]; however, this reduces the
285 generalizability of the findings (Würbel, 2000), and thus has been disallowed by the National
286 Institutes of Health in the US; (4) increasing the variance in the predictor variable(s); for
287 example, including animals with a greater age range if studying correlates of senescence; (5)
288 using subjects as their own controls (e.g. testing each animal after a saline injection as well as
289 a hormone injection). However, we argue that there is an over-arching research problem that
290 typically supersedes tweaks made to experimental designs – the focus on the ubiquitous *P*
291 value when interpreting data analyses. Regardless of the experimental design, due to some
292 intrinsic frailties of *P* value-based data analysis, such studies will usually have employed a
293 sample size too small for robust conclusions to be made.

294 ***Reduction... in the use of the P value for data interpretation***

295 Typically, the number of animals included in an experiment is determined using statistical
296 power analysis to calculate the sample size required for an estimated probability of correctly
297 rejecting the null hypothesis. Statistical power of 80% is the norm (Cohen, 1988), which
298 means that when the null hypothesis being tested is false, a statistically significant result will
299 be reported 80% of the time. The number of animals necessary to achieve 80% power in a
300 well-designed experiment is deemed ‘required’ and is thus ethically acceptable according to
301 the 3Rs philosophy. Power analysis is intimately tied to the *P* value, since the latter is used to
302 decide whether the null hypothesis is rejected or not (and thus whether a finding is deemed
303 ‘significant’).

304 Recently it has become evident that many scientific findings are not reproducible
305 (Baker, 2016; Collaboration, 2015), shaking the pursuit of science to its core (Economist,
306 2013; Freedman et al., 2015; Mobley et al., 2013; Ioannidis, 2005). To conduct a study on
307 animals that is not reproducible is fundamentally counter to the 3Rs principle; animals have
308 been used in fruitless and even misleading experiments (Button et al., 2013). Many authors
309 have discussed how to combat irreproducibility (Freedman et al., 2015; Ioannidis et al., 2015;
310 McNutt, 2014; Nosek et al., 2015; Reproducibility-Initiative, 2014; Woolston, 2014). While
311 only a few publications have targeted the *P* value as a potential culprit, these papers have
312 compellingly argued that over-reliance on *P* values for data interpretation is helping drive
313 irreproducibility (Colquhoun, 2014; Cumming, 2008; Halsey et al., 2015; Nuzzo, 2014;
314 although other factors, such as lack of homogeneity in protocols, can contribute). Crucially,
315 this is the case even when statistical power is 80%.

316 First, interpretation of data based on *P* values will often produce misleading
317 conclusions owing to the false discovery rate, which is the probability of calculating a *P* value
318 sufficiently low to claim ‘significance’ when in fact the null hypothesis is true (Colquhoun,
319 2014). Assuming *P* values <0.05 are those considered ‘significant’, and that the proportion of
320 studies conducted where the null hypothesis is false is 10%, the false discovery rate is at least
321 36% according to Colquhoun (2014) and Sellke et al. (2001) (although it could be less in
322 research fields where scientists conduct the experiments they anticipate are likely to return
323 ‘significant’ results; Wacholder et al., 2004). Second, models have highlighted that *P*
324 typically varies dramatically between replicates of a study, and this ‘fickleness’ in *P* is present
325 even when statistical power is quite high (Cumming, 2008; Halsey et al., 2015).

326 In the biological disciplines, average statistical power, including in fields such as
327 neuroscience (Button et al., 2013; Macleod et al., 2009) and behavioural ecology (Jennions
328 and Møller, 2003), is consistently less than 50% and often considerably lower (Smith et al.,

329 2011). Such low power exacerbates the problem of false discoveries and P 's inherent
330 fickleness. Simply put, when a study reports a P value indicating strong evidence against the
331 null hypothesis, there is every chance that a replication of that study would report a P value
332 indicating much less evidence against the null hypothesis (and *vice versa*). Furthermore,
333 studies that do yield significant results tend to exaggerate the true effect size, and this is
334 exacerbated when statistical power is low (Button et al., 2013; Halsey et al., 2015).
335 Consequently, the interpretation of one-off experiments based on the P value may explain
336 why so many studies are irreproducible (Halsey et al., 2015).

337 There are further valid reasons to question the usefulness of P for data interpretation
338 (Cohen, 1994; Tressoldi, 2013). Of particular relevance is that significance testing of the null
339 hypothesis only allows us to ask a very limited question about our data, simply 'is there or
340 isn't there?'. For example, 'is there a difference in metabolic rates between two mouse
341 strains?' or 'is there a relationship between metabolic rate and risk-taking behaviour?'. Given
342 a large enough study we can always find a difference, or a relationship, to some degree
343 (Cohen, 1994; Loftus, 1993), and so answering these questions tells us very little about our
344 data.

345 Once these sobering facts about the P value have sunk in, the only conclusion open to
346 us is to greatly reduce, or even discard, our use of P in statistical analyses. Although P values
347 are entrenched within the research culture of experimental biology, when animal health and
348 welfare is at stake it is surely unethical to continue using an inadequate statistical index for
349 data interpretation. In turn, the use of power analysis to calculate the necessary numbers of
350 experimental animals becomes questionable.

351 *What alternatives do we have?*

352 There are several alternatives available, such as Bayesian analysis and the Akaike Information
353 Criterion, although no method is perfect (Ellison et al., 2014). We suggest that instead of
354 focussing on the standard approach of ‘is there or isn’t there?’, it is more illuminating to ask
355 ‘how big is the difference?’ or ‘how strong is the relationship?’, coupled with the question
356 ‘how precise is the estimate of the magnitude of the difference or relationship?’. The answers
357 to these two questions not only tell us if there is a difference or a relationship, but much more
358 by also informing us of its (estimated) magnitude coupled with how precise that estimate is
359 likely to be; all in all – a much better use of experimental animals. The most straightforward
360 way to analyse our data in order to answer these two questions is first to calculate the effect
361 size – the size of the difference between conditions or the strength of the correlation between
362 two variables. Second, because our experiment only estimates rather than measures the
363 population effect size, we should also provide the confidence intervals for that estimate, to
364 indicate how precisely the effect is known (Cumming, 2008; Halsey et al., 2015; Johnson,
365 1999; Nakagawa and Cuthill, 2007).

366

367 *More is less*

368 When basing data interpretation on effect size estimates and their precision, the number of
369 experimental animals required should relate to how precisely we need our sample to represent
370 the population. ‘Planning for precision’ calculates the sample size required for the effect size
371 needed in order to provide a defined degree of precision, based on the predicted effect size
372 and variance within the data (Maxwell et al., 2008). Currently, few studies take this approach
373 – when presented, 95% confidence intervals are often large, showing poor precision; a fact
374 that may explain the omission of confidence intervals from many figures. But it is important
375 that we are aware of the level of precision (or otherwise) in our experimental results (rather

376 than hiding it behind a *P* value; Cumming, 2008); if necessary we should adjust our sample
377 size accordingly. Designing experiments around precision rather than power analysis is likely
378 to increase experimental animal numbers. However, if the results are more meaningful then
379 this should reduce the number of experiment repetitions needed, hence reducing experimental
380 animal numbers in the long run.

381 Perhaps the strongest argument for analyses based on effect sizes combined with
382 confidence intervals is that where multiple studies on a particular question have been
383 published and this information included, it can then be combined in a meta-analysis, enabling
384 us to home in on the statistical truth (e.g. Sena et al., 2010). Typically, the confidence
385 intervals around an effect size calculated from meta-analysis are much smaller than those of
386 the individual studies (Cohn and Becker, 2003), thus giving a much clearer picture about the
387 true, population-level effect size (Fig. 3). Indeed, sample sizes required to detect effect sizes
388 with suitable precision are often prohibitive or deemed unethical for individual researchers,
389 necessitating future meta-analyses (Maxwell et al., 2008). And meta-analyses are efficient on
390 experimental animal numbers. First, where a meta-analysis is undertaken solely on previously
391 published data, it represents an experiment-free study; the ultimate in 3Rs Reduction. Second,
392 where multiple studies of a similar nature are conducted on a relatively intractable research
393 question (Nature Magazine, 2016), within as well as across publications (Harris et al., 2014),
394 meta-analyses give good indication of when such replicate experiments are no longer
395 necessary (Fig. 3). However, the Achilles heel of the meta-analysis is the ‘file drawer
396 phenomenon’. Data on animal experiments are often filed away and not published if found to
397 be ‘non-significant’ (Dwan et al., 2013) – another example of the need to remove the focus
398 from the *P* value. Yet the results of all robust and relevant studies provide invaluable grist to
399 the mill for a future meta-analysis, regardless of their supposed ‘interest’, and meta-analyses
400 often highlight approximate agreements between multiple studies that appear contradictory

401 when viewed as providing either ‘significant’ or ‘non-significant’ findings. Indeed, filing
402 away uninteresting data skews the distribution of published data and distorts the truth, which
403 in the long run will lead to a greater overall number of animals being subjected to experiments.
404 It is therefore essential for 3Rs Reduction, and for the pursuit of science in general, that all
405 valid experimental data are published. Fortunately, there are progressively more journals that
406 explicitly judge whether a submission is suitable for publication on merit alone without
407 consideration of impact. And for those researchers who insist on *P* value-based interpretations,
408 the revised version of the European code of research integrity states that non-significant
409 results should be treated as valid findings worthy of publication {Wissenschaftsstiftung, 2017
410 #4816; Box 2}; a standard that the EU’s Horizon 2020 programme now expects its recipients
411 to abide by.

412

413 **CONCLUSIONS**

414 Here, we have highlighted the benefits of adopting the 3Rs into experimental biology: there
415 are advantages for the quality of data obtained, the robustness of the experimental design –
416 including statistical analyses – and the validity of the scientific outputs. Adopting an ethical
417 approach allows researchers to justify their studies not only to legislators and ethics
418 committees but also to funding bodies and the public.

419 Refinement of both husbandry practices and experimental design is an important
420 aspect of the 3Rs. Developing optimal husbandry and housing to ensure animal health and
421 welfare and a means of monitoring animal welfare before, during and after experiments is
422 paramount. Additionally, experimental design should be carefully thought through and
423 possibly logged in a database prior to the study commencing. NC3Rs have developed an
424 online tool – the Experimental Design Assistant (EDA, 2017) – to assist researchers in

425 developing their approach and to encourage randomisation and blinding where possible to
426 prevent bias. Reproducibility and translatability of published studies has recently come under
427 scrutiny, and where this is due to the lack of full reporting of methods, many journals are
428 tackling this via adopting the ARRIVE guidelines, using a checklist to ensure that all
429 experimental details are provided to allow researchers to fully replicate studies (ARRIVE,
430 2017). To encourage ethical thinking, we propose that all journals reporting animal research
431 could ask authors to include a section on ethical justification of the study so that the 3Rs
432 thought-process is clear (some journals already do).

433 In terms of Reduction, there is a conflict between minimising the number of animals
434 used versus recent revelations that published results may not be robust. How can a balance be
435 struck between keeping animal use as low as possible while including a large enough ‘N’ to
436 ensure the study was worth doing? In debating this question it is counter-productive to couch
437 it within the concept of power analysis and implicitly therefore the fickle *P* value. We need to
438 put the health and welfare of animals ahead of our statistical traditions. In turn, when
439 designing experiments we should plan for precision; we urge biology journals to encourage
440 this analysis rather than requesting power analysis information as they do at present. For
441 authors, we suggest some draft text that could form the basis of a statement included in the
442 Methods section of a manuscript to highlight and justify the authors’ focus on statistical
443 analyses other than the *P* value (Box 2).

444 The biggest Reduction sin of all is not publishing our data – animals have been used
445 and zero knowledge accumulated. We must strive to publish all results, however interesting or
446 otherwise we consider them to be, to make full use of the experimental animals and to
447 maximise the accuracy of future meta-analyses. Journals publishing non-significant results
448 and demanding high clarity are invaluable in supporting this endeavour, ensuring the lives of
449 all animals used are respected.

450 Developments in the use of non-protected species and young forms alongside the
451 validation of cell and tissue preparations in a variety of contexts leave much scope for
452 considering Replacement. Other options, such as the use of human volunteers (e.g. Halsey et
453 al. 2017), human samples or modelling of existing data sets, may avoid animal use. However,
454 it is crucially important that when animals are used the species chosen is relevant to the
455 question being addressed; the careful choice of model underpins the utility of the scientific
456 outcomes from any study. Therefore, Relevance could be considered as a 4th R. The
457 importance of Relevance is highlighted by scientists that, for example, interrogate questions at
458 the species-specific level, particularly where adult forms cannot be replaced by juveniles. In
459 this situation, Replacement is not an R that can be deployed. In turn, Refinement and
460 Reduction become all the more important levers to pull in seeking to maximise the health and
461 welfare of the experimental animals.

462

463 **Acknowledgements**

464 We are grateful to the organisations that sponsored and made contributions to the SEB
465 Animal Section Symposium “Implementing the 3Rs: Improving experimental approaches in
466 animal biology” including ASAB Workshop funding; contributions to speakers’ expenses
467 and/or provision of speakers by National Centre for the 3Rs (NC3Rs UK, Nathalie Percie du
468 Sert and Mark Prescott); Royal Society for the Prevention of Cruelty to Animals (RSPCA,
469 Penny Hawkins); Laboratory Animal Science Association (LASA, Caroline Chadwick);
470 Biotechnology and Biological Sciences Research Council (BBSRC, Lydia Darragh) and
471 Understanding Animal Research (UAR, Wendy Jarrett); and to ASAB, RSPCA and
472 Universities Federation for Animal Welfare (UFAW, Huw Golledge) for sponsoring
473 presentation prizes. We also thank the participants of this symposium for their presentations

474 and open sharing of ideas. We are grateful to Gordon Drummond for his feedback on the
475 Reduction section of this article, and to Malcolm Macleod for help in sourcing a suitable
476 example of a cumulative meta-analysis.

477

478 **Competing interests**

479 The authors declare no competing interests.

480

481 **References**

482 **Ankley, G. T., Bennett, R. S., Erickson, R. J., Hoff, D. J., Hornung, M. W., Johnson, R.**
483 **D., Mount, D. R., Nichols, J. W., Russom, C. L., Schmieder, P. K., Serrano, J. A., Tietge,**
484 **J. E. and Villeneuve, D. L.** (2010). Adverse outcome pathways: a conceptual framework to
485 support ecotoxicology research and risk assessment. *Environ. Toxicol. Chem.* **29**, 730-741.

486 **ARRIVE** (2017). <http://www.nc3rs.org.uk/arrive-guidelines>

487 **Baker, M.** (2016). 1,500 scientists lift the lid on reproducibility. *Nature* **533**, 452-454.

488 **Baron, M. G., Mintram, K. S., Owen, S. F., Hetheridge, M. J., Moody, A. J., Purcell, W.**
489 **M., Jackson, S. K. and Jha, A. N.** (2017). Pharmaceutical Metabolism in Fish: Using a 3-D
490 Hepatic In Vitro Model to Assess Clearance. *PLoS One.* **12**:e0168837.

491 **Baron, M. G., Purcell, W. M., Jackson, S. K., Owen, S. F. and Jha, A. N.** (2012). Towards
492 a more representative in vitro method for fish ecotoxicology: morphological and biochemical
493 characterisation of three-dimensional spheroidal hepatocytes. *Ecotoxicol.* **21**, 2419-2429.

494 **Bols, N. C., Barlian, A., Chirinotrejo, M., Caldwell, S. J., Geogan, P. and Lee, L. E. J.**
495 (1994). Development of a cell line from the primary cultures of rainbow trout, *Oncorhynchus*
496 *mykiss* (Walbaum), gills. *J. Fish Dis.* **17**, 601-611.

497 **Bols, N. C., Dayeh, V. R., Lee, L. E. J. and Schirmer, K.** (2005). Use of fish cell lines in
498 the toxicology and ecotoxicology of fish. In *Biochemistry and Molecular Biology of Fishes*
499 Vol 6, Eds T. M. Moon & Mommensen, T. P. Elsevier, Amsterdam, Netherlands.

500 **Boos, D. D. and Stefanski, L. A.** (2011). P-Value precision and reproducibility. *The*
501 *American Statistician* **65**, 213-221.

502 **Burden, N., Benstead, R., Clook, M., Doyle, I., Edwards, P., Maynard, S.K., Ryder, K.,**
503 **Sheahan,, D., Whale, G., van Egmond, R., Wheeler, J.R. and Hutchinson T.H.**
504 (2016).Advancing the 3Rs in regulatory ecotoxicology: A pragmatic cross-sector approach.
505 *Integr. Environ. Assess. Manag.* **12**, 417-421.

506 **Bury,N. R., Schnell, S. and Hogstrand, C.** (2014). Gill cell culture systems as models for
507 aquatic environmental monitoring. *J. exp. Biol.* **217**, 639-650.

508 **Busquets, F., Strecker, R., Rawlings, J. M., Belanger, S. E., Braunbeck, T., Carr, G.J.,**
509 **Cenijn, P., Fochtman, P., Gourmelon, A., Hübeler, N., Kleensang, A., Knöbel, M.,**
510 **Kussatz, C., Legler, J., Lillicrap, A., Martinez-Jeronimo, F., Plleichtner, C., Rzodeczko,**
511 **H., Salinas, E., Schneider, K. E., Scholz, S., van den Brandhof, E-J., van der Ven, L. T.**
512 **M., Walter-Rohde, S., Weight, S., Witters, H. and Halder, M.** (2014). OECD validation
513 study to assess intra- and inter-laboratory reproducibility of the zebrafish embryo toxicity test
514 for acute aquatic toxicity testing. *Regul. Toxicol. Pharmacol.* **69**, 496-511.

515 **Button, K., Ioannidis, J., Mokrysz, C., Nosek, B., Flint, J., Robinson, E. and Munafò, M.**
516 (2013). Power failure: why small sample size undermines the reliability of neuroscience. *Nat.*
517 *Rev. Neurosci* **14**, 365-376.

518 **Carlsson C. and Pärt P.** (2001). 7-Ethoxyresorufin O-deethylase induction in rainbow trout
519 gill epithelium cultured on permeable supports: asymmetrical distribution of substrate
520 metabolites. *Aquat. Toxicol.* **54**, 29-38.

521 **Cohen, J.** (1988). *Statistical power analysis for the behavioural sciences*. Hillside, NJ:
522 Lawrence Earlbaum Associates.

523 **Cohen, J.** (1994). The Earth is round ($p < 0.05$). *Amer. Psychologist* **49**, 997-1003.

524 **Cohn, L. D. and Becker, B. J.** (2003). How meta-analysis increases statistical power.
525 *Psychological Meths.* **8**, 243.

526 **Collaboration, O. S.** (2015). Estimating the reproducibility of psychological science. *Science*
527 *349*.

528 **Colquhoun, D.** (2014). An investigation of the false discovery rate and the misinterpretation
529 of p-values. *Roy. Soci. Open Science* **1**, 140216.

530 **Cowan-Ellsberry, C., Dyer, S. D., Erhardt, S., Bernhard, M. J., Roe, A. L., Dowty, M. E.**
531 **and Weisbrod, A. V.** (2008). Approach for extrapolating in vitro metabolism data to refine
532 bioconcentration factor estimates. *Chemosphere* **70**, 1804 – 1817.

533 **Crossley, M., Staras, K., Kemenes, G.** (2016). A two-neuron system for adaptive goal-
534 directed decision-making in *Lymnaea*. *Nat. Commun.* **7**:11793.

535 **Cruz, S.A., Lin, C.H., Chao, P.L., Hwang, P-P.** (2013). Glucocorticoid receptor, but not
536 mineralocorticoid receptor, mediates cortisol regulation of epidermal ionocyte development

537 and ion transport in zebrafish (*Danio rerio*). *PLoS One* **8**: e77997. **Cumming, G.** (2008).
538 Replication and p intervals. p values predict the future only vaguely, but confidence intervals
539 do much better. *Persp. Psycholog. Sci.* **3**, 286-300.

540 **Cumming, G., Fidler, F. and Vaux, D.** (2007). Error bars in experimental biology. *J. Cell*
541 *Biol.* **177**, 7-11.

542 Dalla Costa, E., Minero, M., Lebelt, D., Stucke, D., Canali, E. and Leach, M. C. (2014)
543 Development of the horse grimace scale (hgs) as a pain assessment tool in horses undergoing
544 routine castration. *PLoS ONE* **9**, e92281.

545 **de Boo, J. and Hendriksen, C.** (2005). Reduction strategies in animal research: a review of
546 scientific approaches at the intra-experimental, supra-experimental and extra-experimental
547 levels. *ATLA* **33**, 369.

548 **Deakin, A. G., Buckley, J., AlZu'bi, H. S., Cossins, A. R., Spencer, J. W., Al'Nuaimy, W.,**
549 **Young, I.S. and Sneddon, L. U.** Automated fish behaviour monitoring: A novel tool to
550 characterize the status of zebrafish. Manuscript submitted.

551 **DePasquale, C., Neuberger, T., Hirrlinger, A. M., & Braithwaite, V. A.** (2016). The
552 influence of complex and threatening environments in early life on brain size and behaviour.
553 *Proc. Roy. Soc. Lond. B*, **283**, 20152564

554 **Dwan, K., Gamble, C., Williamson, P. R. and Kirkham, J. J.** (2013). Systematic review of
555 the empirical evidence of study publication bias and outcome reporting bias — An updated
556 review. *PLoS ONE* **8**, e66844

557 **Economist** (2013). Unreliable Research: Trouble at the Lab. In *The Economist*, pp. 26-30
558 ['Trouble at the Lab']: The Economist Newspaper Limited.

559 **EDA** (2017). <https://eda.nc3rs.org.uk/>

560 **Ellison, A., Gotelli, N., Inouye, B. and Strong, D.** (2014). P values, hypothesis testing, and
561 model selection: it's de'ja` vu all over again. *Ecol.* **95**, 609-610.

562 **Eng, J.** (2003). Sample Size Estimation: How Many Individuals Should Be Studied? 1.
563 *Radiol.* **227**, 309-313.

564 **European Commission** (2015) Communication From The Commission on the European
565 Citizens' Initiative "Stop Vivisection".
566 http://ec.europa.eu/environment/chemicals/lab_animals/pdf/vivisection/en.pdf

567 **Fisher, R.** (1959). *Statistical Methods and Scientific Inference*. New York: Hafner Publishing.

568 **Freedman, L. P., Cockburn, I. M. and Simcoe, T. S.** (2015). The Economics of
569 Reproducibility in Preclinical Research. *PLoS Biol* **13**, e1002165.

570 **Gardner, C. J., Deeming, D. C., Wellby, I., Soulsbury, C. D. and Eady, P. E.** (2015).
571 Effects of surgically implanted tags and translocation on the movements of common bream
572 *Abramis brama* (L.). *Fisheries Res.* **167**, 252-259.

573 **Geppert, M., Sigg, L. and Schirmer, K.** (2016). A novel two-compartment barrier model for
574 investigating nanoparticle transport in fish intestinal epithelial cells. *Environ. Sci. Nano.* **3** ,
575 388.

576 **Guh, Y-J., Lin, L-H. and Hwang, P-P.** (2015) Osmoregulation in zebrafish: ion transport
577 mechanisms and functional regulation. *EXCLI J.* **14**: 627-659.

578 **Halsey, L. G., Curran-Everett, D., Vowler, S. and Drummond, G.** (2015). The fickle P
579 value generates irreproducible results. *Nature Meths.* **12**, 179-185.

580 **Halsey, L.G., Coward, S. R. L., Crompton, R. H. and, Thorpe, S. K. S.** (2017) Practice
581 makes perfect: performance optimisation in ‘arboreal’ parkour athletes illuminates the
582 evolutionary ecology of great ape anatomy. *J. Human Evol.* **103**, 45-52.

583 **Halsey, L. G.** (2007). 'Traversities of justice': The noise to signal ratio in association football.
584 *Soccer and Society* **8**, 68-74.

585 **Handy, R. D., Musonda, M. M., Phillips, C. and Falla, S. J.** (2000). Mechanisms of
586 gastrointestinal copper absorption in the African walking catfish: Copper dose-effects and a
587 novel anion-dependent pathway in the intestine. *J. exp. Biol.* **203**, 2365-2377.

588 **Henn, K. and Braunbeck, T.** (2011). Dechoriation as a tool to improve the fish embryo
589 toxicity test (FET) with the zebrafish (*Danio rerio*). *Comp. Biochem. Physiol.* **153C**, 91-98.

590 **Holmes, A. M., Emmans, C. J., Jones, N., Coleman, R., Smith, T. E. and Hosie, C. A.**
591 (2016). Impact of tank background on the welfare of the African clawed frog, *Xenopus laevis*
592 (Daudin). *Appl. Anim. Behav. Sci.* **185**, 131-136.

593 **Hopkins, M. E. and Milton, K.** (2016). Adverse effects of ball-chain radio-collars on female
594 mantled howlers (*Alouatta palliata*) in Panama. *Internat. J. Primatol.*, **37**, 213-224.

595 **Hurst, J. L. and West, R. S.** (2010). Taming anxiety in laboratory mice. *Nat Methods.* **7**,
596 825-826.

597 **Incardona, J. P. and Scholz, N. L.** (2016). The influence of heart developmental anatomy on
598 cardiotoxicity-based adverse outcome pathways in fish. *Aquat. Toxicol.* **177**, 515-525.

599 **Ioannidis, J. P.** (2005). Why most published research findings are false. *PLoS Med* **2**, e124.

600 **Ioannidis, J. P. A., Fanelli, D., Dunne, D. D. and Goodman, S. N.** (2015). Meta-research:
601 Evaluation and Improvement of Research Methods and Practices. *PLoS Biol* **13**, e1002264.

602 **Jennions, M. D. and Møller, A. P.** (2003). A survey of the statistical power of research in
603 behavioral ecology and animal behavior. *Behav. Ecol.* **14**, 438-445.

604 **Johnson, D.** (1999). The insignificance of statistical significance testing. *J. Wildlife Manag.*
605 **63**, 763-772.

606 **Kalmar, I. D., Janssens, G. P. J. and Moons, C. P. H.** (2010). Guidelines and ethical
607 considerations for housing and management of psittacine birds used in research. *ILAR J.* **51**,
608 409-423.

609 **Kawano, A., Haiduk, C., Schirmer, K., Hanner, R., Lee, L. E. J., Dixon, B. and Bols, N.**
610 **C.** (2011). Development of a rainbow trout intestinal epithelial cell line and its response to
611 lipopolysaccharide. *Aquacul. Nut.* **17**, E241-E252.

612 **Keating, S. C. J., Thomas, A. A., Flecknell, P. A. and Leach, M. C.** (2012). Evaluation of
613 EMLA cream for preventing pain during tattooing of rabbits: Changes in physiological,
614 behavioural and facial expression responses. *PLoS One* **7**, e44437

615 **Knight, K.** (2016). Implementing the 3Rs: improving experimental approaches in animal
616 biology. *J. Exp. Biol.* **219**, 2414-2415.

617 **Lammer, E., Kamp, H., Hisgen, V., Koch, M., Reinhard, D., Salinas, E. R., Wendler, K.,**
618 **Zok, S. and Braunbeck, T.** (2009). Development of a flow-through system for the fish
619 embryo toxicity test (FET) with the zebrafish. *Toxicol. In Vitro* **23**, 1436 – 1442.

620 **Langford, D. J., Bailey, A. L., Chanda, M. L., Clarke, S. E., Drummond, T. E., Echols, S.,**
621 **Glick, S., Ingrao, J., Klassen-Ross, T., LaCroix-Fralish, M. L., Matsumiya, L., Sorge, R.**
622 **E., Sotocinal, S. G., Tabaka, J. M., Wong, D., van den Maagdenberg, A. M. J. M.,**
623 **Ferrari, M. D., Craig, K. D. and Mogil, J. S.** (2010). Coding of facial expressions of pain in
624 the laboratory mouse. *Nat. Meths.* **7**, 447-449.

625 **Lavine, M.** (2014). Comment on Murtaugh. *Ecol.* **95**, 642-645.

626 **Lillicrap, A., Belanger, S., Burden, N., Du Pasquier, D., Embry, M., Halder, M., Lampi,**
627 **M. A., Lee, L., Norberg-King, T., Rattner, B. A., Schirmer, K. and Thomas, P.** (2016).
628 Alternative approaches to vertebrate ecotoxicity tests in the 21st Century: A review of
629 developments over the last 2 decades and current status. *Environ. Toxicol. Chem.* **35**, 2637-
630 2646.

631 **Liu, F., Huang, J., Ning, B., Liu, Z., Chen, S. and Zhao, W.** (2016) Drug discovery via
632 human-derived stem cell organoids. *Front. Pharmacol.* **7**:334

633 **Loftus, G. R.** (1993). A picture is worth a thousand p values: On the irrelevance of
634 hypothesis testing in the microcomputer age. *Behav. Res. Meths. Instruments Comps.* **25**, 250-
635 256.

636 **Lopez-Luna, J., Al-Jubouri, Q., Al-Nuaimy, W. and Sneddon, L. U.** (2017a). Impact of
637 analgesic drugs on the behavioural responses of larval zebrafish to potentially noxious
638 temperatures. *Appl. Anim. Behav. Sci.* **188**, 97–105.

639 **Lopez-Luna, J., Al-Jubouri, Q., Al-Nuaimy, W. and Sneddon, L.U.** (2017b). Activity
640 reduced by noxious chemical stimulation is ameliorated by immersion in analgesic drugs in
641 zebrafish. *J. Exp. Biol.* **220**, 1451-1458.

642 **Lukowiak, K., Sunada, H., Teskey, M., LukowiaK, K. And Dalesman, S.** (2014).
643 Environmentally relevant stressors alter memory formation in the pond snail *Lymnaea*. *J. Exp.*
644 *Biol.* **217**, 76-83

645 **Macleod, M. R., Fisher, M., O'Collins, V., Sena, E. S., Dirnagl, U., Bath, P. M., Buchan,**
646 **A., van der Worp, H. B., Traystman, R. J. and Minematsu, K.** (2009). Reprint: Good

647 laboratory practice: preventing introduction of bias at the bench. *J. Cerebral Blood Flow*
648 *Metab.* **29**, 221-223.

649 **Maxwell, S., Kelley, K. and Rausch, J.** (2008). Sample size planning for statistical power
650 and accuracy in parameter estimation. *Ann. Rev. Psychol.* **59**, 537-563.

651 **McClelland, G. H.** (2000). Increasing statistical power without increasing sample size.

652 **NC3Rs** (2017). <http://www.nc3rs.org.uk/grimacescales>.

653 **Maxwell, S., Kelley, K. and Rausch, J.** (2008). Sample size planning for statistical power
654 and accuracy in parameter estimation. *Ann. Rev. of Psychol.* **59**, 537-563.

655 **McNutt, M.** (2014). Journals unite for reproducibility. *Science* **346**, 679.

656 **Minghetti, M. and Schirmer, K.** (2016). Effect of media composition on bioavailability and
657 toxicity of silver and silver nanoparticles in fish intestinal cells (RTgutGC). *Nanotoxicol.*, **10**,
658 1529 – 1534.

659 **Mobley, A., Linder, S. K., Braeuer, R., Ellis, L. M. and Zwelling, L.** (2013). A Survey on
660 Data Reproducibility in Cancer Research Provides Insights into Our Limited Ability to
661 Translate Findings from the Laboratory to the Clinic. *PLoS ONE* **8**, e63221.

662 **Muthuswamy, S.K.** (2017). Bringing together the organoid field: from early beginnings to
663 the road ahead. *Development* **144**, 963-967.

664 **Nakagawa, S. and Cuthill, I.** (2007). Effect size, confidence interval and statistical
665 significance: a practical guide for biologists. *Biological Rev.* **82**, 591-605.

666 **Nature Magazine.** (2016). Go forth and replicate! *Nature* **536**, 373.

667 **Nichols, J. W., Fitzsimmons, P. N. and Burkhard, L. P.** (2007). In vitro-in vivo
668 extrapolation of quantitative hepatic biotransformation data for fish. II Modeled effects on
669 chemical bioaccumulation. *Environ. Toxicol. Chem.* **26**, 1304-1319.

670 **Nichols, J.W., Huggett, D.B., Arnot, J.A., Fitzsimmons, P.N. and Cowan-Ellsbery, C.E.**
671 (2013). Toward improved models for predicting bioconcentration of well-metabolized
672 compounds by rainbow trout using measured rates of in vitro intrinsic clearance. *Environ.*
673 *Toxicol. Chem.* **32**, 1611-1622.

674 **Nichols, J. W., Schultz, I. R. and Fitzsimmons, P. N.** (2006). In vivo-in vitro extrapolation
675 of quantitative hepatic biotransformation data for fish. I A review of methods, and strategies
676 for incorporating intrinsic clearance estimates into chemical kinetic models. *Aquat. Toxicol.*
677 **78**, 74-90.

678 **Noldus** (2016). Sense Well, www.noldus.com/projects/sensewell

679 **Nosek, B. A., Alter, G., Banks, G. C., Borsboom, D., Bowman, S. D., Breckler, S. J.,**
680 **Buck, S., Chambers, C. D., Chin, G., Christensen, G. et al.,** (2015). Promoting an open
681 research culture. *Science* **348**, 1422-1425.

682 **Nüßer, L.K., Skulovich, O., Hartmann, S., Seiler, T-B., Cofalla, C., Schuttrumpf, H.,**
683 **Hollert, H., Salomons, E. and Ostfeld, A.** (2016). A sensitive biomarker for the detection of
684 aquatic contamination based on behavioural assays using zebrafish larvae. *Ecotoxicol.*
685 *Environ. Saf.* **133**, 271-280.

686 **Nuzzo, R.** (2014). Statistical Errors. *Nature* **506**, 150-152.

687 **OECD Guidelines for testing chemicals. Test No. 203: Fish, Acute Toxicity Test** (1992).
688 www.oecd-library.org

689 **OECD Guidelines for testing chemicals. Test No. 305: Bioaccumulation in Fish:**
690 **Aqueous and Dietary Exposure** (2012). www.oecd-library.org

691 **O'Farrell, A. C., Shnyder, S. D., Marston, G., Coletta, P. L. and Gill, J. H.** (2013). Non-
692 invasive molecular imaging for preclinical cancer therapeutic development. *Br J Pharmacol.*
693 **169**, 719–735.

694 **Otto, G. P., Cocorocchio, M., Munoz, L., Tyson, R. A., Bretschneider, T. and Williams,**
695 **R. S.** (2016). Employing Dictyostelium as an Advantageous 3Rs Model for Pharmacogenetic
696 Research. *Methods Mol. Biol.* **1407**, 123-130.

697 **Pew Research Center** (2015). “Public and Scientists’ Views on Science and Society”
698 <http://www.pewinternet.org/2015/01/29/public-and-scientists-views-on-science-and-society/>

699 **Phillips, R. A., Green, J. A., Phalan, B., Croxall, J. P. and Butler, P. J.** (2003). Chick
700 metabolic rate and growth in three species of albatross: a comparative study. *Comp. Biochem.*
701 *Physiol. A*, **135**, 185-193.

702 **Pounder, K. C., Mitchell, J. L., Thomson, J. S., Pottinger, T.G., Buckley, J. and Sneddon,**
703 **L.U.** (2016). Does environmental enrichment promote recovery from stress in rainbow trout?
704 *Appl. Anim. Behav. Sci.* **176**, 136–142

705 **Reproducibility Initiative.** (2014). **Reproducibility Initiative.** In
706 <http://validation.scienceexchange.com/#/reproducibility-initiative>, vol. 2014.

707 **Rushen, J., Chapinal, N. and de Passillé, A. M.** (2012). Automated monitoring of
708 behavioural-based animal welfare indicators. *Animal Welf.* **21**: 339-350

709 **Russell, W. M. S., and Burch, R. L.** (1959). *The principles of humane experimental*
710 *technique*. London: Methuen.

711 **Russom, C. L., Bradbury, S. P., Broderius, S. J., Hammermeister, D. E. and Drummond,**
712 **R. A.** (1997). Predicting modes of toxic action from chemical structure: Acute toxicity in the
713 fathead minnow (*Pimephales promelas*). *Environ. Toxicol. Chem.* **16**, 948-967.

714 **Schnell, S., Stott, L. C., Hogstrand, C., Wood, C. M., Kelly, S. P., Pärt, P., Owen, S. F.**
715 **and Bury N. R.** (2016). Procedures for the reconstruction, primary culture and experimental
716 use of rainbow trout epithelia. *Nature Prot.* **11**, 490-498.

717 **Scholz, S., Ortmann, J., Klüver, N. and Léonard, M.** (2014). Extensive review of fish
718 embryo acute toxicities for the prediction of GHS acute systemic toxicity categories. *Regul.*
719 *Toxicol. Pharmacol.* **69**, 572-579.

720 **Schroeder, P., Jones, S., Young, I. S. and Sneddon, L. U.** (2014). What do zebrafish want?
721 Impact of social grouping, dominance and gender on preference for enrichment. *Lab. Anim.*
722 **48**, 328–337.

723 **Schroeder, P. and Sneddon, L. U.** (2017). Exploring the efficacy of immersion analgesics in
724 zebrafish using an integrative approach. *Appl. Anim. Behav. Sci.* **187**, 93–102.

725 **Sellke, T., Bayarri, M. and Berger, J. O.** (2001). Calibration of p values for testing precise
726 null hypotheses. *The American Statistician* **55**, 62-71.

727 **Sena, E. S., Briscoe, C. L., Howells, D. W., Donnan, G. A., Sandercock, P. A. and**
728 **Macleod, M. R.** (2010). Factors affecting the apparent efficacy and safety of tissue
729 plasminogen activator in thrombotic occlusion models of stroke: systematic review and meta-
730 analysis. *J. Cerebral Blood Flow Metab.* **30**, 1905-1913.

731 **Singhal, G., Jaehne, E. J., Corrigan, F., and Baune, B. T.** (2014). Cellular and molecular
732 mechanisms of immunomodulation in the brain through environmental enrichment. *Front.*
733 *Cell. Neurosci.* **8**, 97.

734 **Smith, D. R., Hardy, I. C. and Gammell, M. P.** (2011). Power rangers: no improvement in
735 the statistical power of analyses published in Animal Behaviour. *Anim. Behav.* **81**, 347-352.

736 **Sneddon, L. U.** (2015). Pain in aquatic animals. *J. Exp. Biol.* **218**, 967-976

737 **Sneddon, L. U., Elwood, R. W. Adamo S. and Leach M. C.** (2014). Defining and assessing
738 pain in animals. *Anim. Behav.* **97**, 201-212.

739 **Sorge, R. E., Martin, L. J., Isbester, K. A., Sotocinal, S. G., Rosen, S., Tuttle, A. H.,**
740 **Wieskopf, J. S., Acland, E. L., Dokova, A. and Kadoura, B.** (2014). Olfactory exposure to
741 males, including men, causes stress and related analgesia in rodents. *Nature Meths.* **11**, 629-
742 632.

743 **Sotocinal, S.G., Sorge, R.E., Zaloum, A., Tuttle, A.H., Martin, L.J., Wieskopf, J. S.,**
744 **Mapplebeck, J. C. S., Wei, P., Zhan, S., Zhang, S., McDougall, J. J., King, O. D. and**
745 **Mogil, J. S.** (2011). The Rat Grimace Scale: a partially automated method for quantifying
746 pain in the laboratory rat via facial expressions. *Mol. Pain* **7**, 55.

747 **Stadnicka-Michalak, J., Schirmer, K. and Ashauer, R.** (2015). Toxicology across scales:
748 cell population growth in vitro predicts reduced fish growth. *Science Adv.* **1**:e1500302

749 **Strähle, U., Scholz, S., Geisler, R., Greiner, P., Hollert, H., Rastegar, S., Schumacher, A.,**
750 **Selderslaghs, I., Weiss, C., Witters, H. and Braunbeck, T.** (2012). Zebrafish embryos as an
751 alternative to animal experiments--a commentary on the definition of the onset of protected
752 life stages in animal welfare regulations. *Reprod Toxicol.* **33**,128-32.

753 **Tanneberger, K., Knöbel, M., Busser, F. J. M., Sinnige, T.L., Hermens, J. L. M. and**
754 **Schirmer, K.** (2013). Predicting fish acute toxicity using a fish gill cell line-based toxicity
755 assay. *Environ. Sci. Technol.* **47**, 1110-1119.

756 **Tazawa, H., Aliyama, R., Moriya, K.** (2002). Development of cardiac rhythms in birds.
757 *Comp. Biochem, Physiol* **132A**, 675-689.

758 **Tressoldi, P. E., Giofré, D., Sella, F. and Cumming, G.** (2013). High Impact=High
759 Statistical Standards? Not Necessarily So. *PLoS ONE* **8**, e56180.

760 **Uchea, C., Owen, S. F. and Chipman, J. K.** (2015). Functional xenobiotic metabolism and
761 efflux transporters in trout hepatocyte spheroid cultures. *Toxicol. Res.* **4**, 494-507.

762 **van Helden, J.** (2016). Confidence intervals are no salvation from the alleged fickleness of
763 the P value. *Nat. Meth.* **13**, 605-606.

764 **Villeneuve, D., Volz, D. C., Embry, M.R., Ankley, G .T., Belanger, S.E., Léonard, M.,**
765 **Schirmer, K., Tanguay, R., Truong, L. and Wehmas, L.** (2014). Investigating alternatives
766 to the fish early-life stage test: a strategy for discovering and annotating adverse outcome
767 pathways for early fish development. *Environ. Toxicol. Chem.* **33**, 158-169

768 **Wacholder, S., Chanock, S., Garcia-Closas, M. and Rothman, N.** (2004). Assessing the
769 probability that a positive report is false: an approach for molecular epidemiology studies. *J.*
770 *Nat. Cancer Institute* **96**, 434-442.

771 **Weisbrod, A.V., Sahi, J., Segner, H., James, M. O., Nichols, J., Schultz, I., Erhardt, S.,**
772 **Cowan-Ellsberry, C., Bonnell, M. and Hoeger, B.** (2009). The state of in vitro science for
773 use in bioaccumulation assessments for fish. *Environ. Toxicol. Chem.* **28**, 86-96.

774 **Wissenschaftsstiftung, E.** (2017). The European Code of Conduct for Research Integrity.
775 Revised Edition.

776 **Wittwehr, C., Aladjov, H., Ankley, G., Byrne, H. J., de Knecht, J., Heinzle, E.,**
777 **Klambauer, G., Landesmann, B., Luijten, M., MacKay, C., Maxwell, G., Meek, M. E.,**

778 **Paini, A., Perkins, E., Sobanski, T., Villeneuve, D., Waters, K. M. and Whelan, M.**
779 (2017). How adverse outcome pathways can aid the development and use of computational
780 prediction models for regulatory toxicology. *Toxicol. Sci.* **155**, 326-336.

781 **Woolston, C.** (2014). A blueprint to boost reproducibility of results: Online commenters
782 show support for a call to shake up science. *Nature.* **513**, 283.

783 **Würbel, H.** (2000). Behaviour and the standardization fallacy. *Nature Genetics* 26, 263-263.

784 **Yozzo, K. L., Isales, G. M., Raftery, T. D. and Volz, D.C.** (2013). High-content screening
785 assay for identification of chemicals impacting cardiovascular function in zebrafish embryos.
786 *Environ. Sci. Technol.* **47**, 11302-11310

787 **Box 1: Which animals are protected under the legislation of selected countries?**

788 Globally, legislation differs between countries and geographical regions. Either all animals
 789 used in research are protected (specific species or ages are not prescribed) or the legislation
 790 identifies which animals at what stage of development are included.

Country or region	Protected animals
Australia	Vertebrates of all developmental stages Cephalopods of all developmental stages
Brazil	All animals
China	All animals
Europe	Adult vertebrates Mammalian, bird and reptile foetuses in last third of development Amphibian and fish at the free-feeding stage Cephalopods at the free feeding stage
India	All animals
South Africa	All vertebrates including eggs, foetuses and embryos Cephalopods Decapods
USA	Warm-blooded vertebrates except farm animals used in food and fibre research, rats of the genus <i>Rattus</i> and mice of the genus <i>Mus</i>

791

792

793 ***Box 2: P is for Publication***

794 Many journals, funding bodies and reviewers like to see *P* values and power analyses. For this
795 reason, experimenters might be concerned about disadvantaging themselves if they become
796 apostates of the *P* value doctrine. They might best be advised to continue reporting *P* values
797 in their manuscripts but to shift the focus of interpretation onto effect sizes. For project
798 proposals, perhaps providing both a power analysis and a plan for precision would be sensible.
799 Below is a text template that can be used for inclusion in the Methods section of manuscripts
800 to flag up that data interpretation will be based on effect sizes, and to justify why, while
801 reassuring that *P* values will remain present:

802 In the current article, the *P* value is treated as a continuous variable (Fisher, 1959; Boos and
803 Stefanski, 2011), and because it is typically highly imprecise it is considered to be only a
804 tentative indication of the strength of evidence for observed patterns in the data (Fisher, 1959;
805 Boos and Stefanski, 2011; Halsey et al., 2015). Primarily, patterns in the data are interpreted
806 from graphs of sample effect sizes and their precision (quantified by 95% confidence intervals)
807 (Lavine, 2014; Loftus, 1993).

808

809 **Figure legends**

810

811 **Fig. 1. Ethical thinking when planning animal experiments from conceiving an**
812 **experiment, applying the 3Rs and finally publication.** The figure shows a diagrammatic
813 representation of the major ethical concepts and key questions that scientists must address
814 under the traditional view of the 3Rs – Reduction, Replacement, Refinement – to justify the
815 use of animals in experimentation, from planning the programme of work through to
816 publication. *Except cephalopods, which are protected animals in Australia, Europe and
817 South Africa as listed in Box 1.

818

819 **Fig. 2. Some examples of studies where refinement has proved to be beneficial to the**
820 **welfare of the experimental animals.** (A) Impact of enrichment (gravel, plastic plant and
821 overhead cover) on improving recovery rates in rainbow trout: mean (\pm SE) opercular beat
822 recovery rate (OBR; beats min⁻¹) post treatment, in rainbow trout held in either enriched
823 (dark bars) or barren (light bars) environments. Recovery OBR rate was estimated for each
824 individual fish by subtracting OBR at time of recovery from OBR rate after either one minute
825 of air emersion (Stress) or after deep-plane anaesthesia, and divided by the time between time
826 points (Adapted from Pounder et al., 2016 with kind permission from Elsevier). (B) Impact of
827 background colour in the tanks of *Xenopus laevis*, demonstrating that a white background
828 results in greater body mass change (BMC, g) than a black background (Taken from Holmes
829 et al., 2016 with kind permission from Elsevier). (C) The use of pain-relieving drugs during
830 recovery from fin clipping in zebrafish ameliorates a reduction in activity. The graph shows
831 the mean percentage change in activity level (number of swimming movements) 80 mins after
832 tail fin clipping without analgesia (Fin clip) or in conjunction with immersion in lidocaine

833 (5mg/L) in zebrafish (adapted from Schroeder & Sneddon, 2017 with kind permission from
834 Elsevier).


835

836 **Fig. 3. Cumulative meta-analysis of the efficacy of lytic treatments (e.g. tissue**
837 **plasminogen activator) in thrombotic animal models of stroke.** The data have been
838 adapted to illustrate key points explained and discussed in this article. Studies are in order of
839 their publication date. The greater the value on the x axis, the greater the positive effect of the
840 treatment. Treatment improves outcome; however, the estimate of efficacy (effect size)
841 decreased as more data became available. This often happens, because studies are typically
842 underpowered and therefore, when statistically significant, tend to overestimate the true effect
843 size (Halsey et al. 2015). Note also the considerable size of the 95% confidence intervals (thin
844 horizontal bars) for the first study and even once the first few studies are combined; this is
845 common and demonstrates the lack of precision that individual studies often provide about the
846 true (population) effect size, but is not apparent when focussing on the associated *P* value.
847 Indeed, focussing on the *P* value of each study to synthesise the findings would return a
848 confused conclusion, since while many of the studies report a statistically significant effect of
849 the treatment (black data points and 95% confidence intervals), many of the studies indicate
850 no treatment efficacy (blue). In contrast, focussing on the effect size and 95% confidence
851 intervals of each study shows a relatively consistent pattern of evidence of treatment efficacy
852 (as illustrated), and estimate accuracy of the degree of treatment efficacy steadily improves as
853 more studies are combined into the meta-analysis. The thick horizontal line shows a
854 suggested approximate date at which the efficacy of the treatment was well known and further
855 studies were unlikely to substantially refine this. Although studies published subsequent to
856 2001/2002 probably included other valuable experiments and/or analyses, this figure
857 illustrates that meta-analyses can inform about when further study of a particular treatment or

858 phenomenon would be unproductive. Heeding such information would reduce the number of
859 animals used in experimental research. This figure was reproduced from Sena et al. (2010)
860 and edited with permission.

861


862 Figure 1



863

864


865 Figure 2



866

867

868 Figure 3



869